GlassScriptPhysician profile
James M Corkum
NPI 1154387280
$5,034.16
in general payments reported to CMS, 2019-2025
32 companies · $868 in 2025
The $868 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $182 · 2021: $818 · 2022: $1,026 · 2023: $866 · 2024: $510 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,227 · Education: $16.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,227.17 |
| Education | $16.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,386.65 | 2019-2025 | Mavyret, Vraylar, Rinvoq |
| Celgene Corporation | $589.38 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $320.86 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $283.98 | 2019-2025 | |
| Gilead Sciences, INC. | $282.34 | 2019-2024 | |
| Redhill Biopharma INC. | $222.04 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Braintree Laboratories, INC. | $213.97 | 2019-2024 | Sutab, Suflave |
| Madrigal Pharmaceuticals | $178.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $166.49 | 2019-2023 | Ocaliva |
| Sanofi-Aventis U.S. LLC | $158.58 | 2021 | |
| Abbott Laboratories | $121.82 | 2022 | |
| Janssen Biotech, INC. | $118.96 | 2019-2025 | Tremfya, Stelara, Simponi |
| Ipsen Biopharmaceuticals, INC | $110.79 | 2024-2025 | Iqirvo, Bylvay |
| Amarin Pharma, INC. | $108.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.88 | 2019-2025 | Gattex |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $95.02 | 2019 | |
| Phathom Pharmaceuticals, INC. | $73.33 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $54.98 | 2019-2022 | |
| Amgen INC. | $53.69 | 2022-2023 | Amjevita, Avsola |
| Ardelyx, INC. | $49.46 | 2023-2024 | Ibsrela |
| Genzyme Corporation | $47.51 | 2024 | |
| Ethicon US, LLC | $42.71 | 2025 | Echelon; Endopath |
| Organon LLC | $36.34 | 2023-2024 | Renflexis, Hadlima |
| Celltrion USA INC. | $32.63 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $29.52 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $28.42 | 2025 | Vowst |
| Olympus America INC. | $27.77 | 2019-2023 | Endoclot Phs |
| Exact Sciences Corporation | $22.20 | 2023 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $20.33 | 2022 | |
| Allergan, INC. | $19.20 | 2019 | |
| Mallinckrodt Hospital Products INC. | $17.51 | 2024 | Terlivaz |
| Micro-Tech Endoscopy USA, INC. | $13.24 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Corkum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.